Jul. 3 at 1:21 PM
$CRDF luckily I diversified into other biotech names. With more or less success. It’s biotech after all. But I did save myself from what would have been bigger losses. My strategy is the following: as soon as there is settlement or legal resolution (or even clarity of lack of termination), I will add again big. Might continue to nibble at it in between but that’s it, just nibbling. I am happy to pay
$2 a share without the legal cloud. And I think all the institutions are in that boat. They cannot afford to take such risks given their fiduciary duty. Retail investors and hedge funds and specialized funds can punt, but many cannot. Risk management would dictate to act with caution. For now
$1.3 is where it’s at. Interesting couple of months ahead to say the least.
